NL-OMON46846已完成2 期
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase - DRI13925
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 17（—）
入选标准
- •Patients need to fulfill all inclusion criteria mentioned below:;1) -Male and female patients aged >=2 and <=17 years at the time of the screening visit.;2) -Diagnosis of rheumatoid factor-negative or rheumatoid factor positive polyarticular Juvenile Idiopathic Arhtritis (JIA) subtype or oligoarticular extended JIA subtype according to the International League of Associations for Rheumatology (ILAR) 2001 Juvenile Idiopathic Arthritis Classification Criteria with at least 5 active joints as per American College of Rheumatology (ACR) definition for *active arthritis* at screening.;3) -Patient with an inadequate response to current treatment and considered as a candidate for a biologic disease-modifying antirheumatic drug (DMARD) as per Investigator*s judgment.
排除标准
- •-Body weight <10 kg or >60 kg.
- •-If non-steroidal anti-inflammatory drugs taken, dose stable for less than 2 weeks prior to the baseline visit and/or dosing prescribed outside of approved label.
- •-If non-biologic DMARD taken, dose stable for less than 6 weeks prior to the baseline visit or at a dose exceeding the recommended dose as per local labeling.
- •-If oral glucocorticoid taken, dose exceeding equivalent prednisone dose 0.5 mg/kg/day (or 30 mg/day) within 2 weeks prior to baseline.
- •-Prior treatment with anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.
- •-Treatment with any biologic DMARD within 5 half-lives prior to the first dose of sarilumab
- •-Treatment with a Janus kinase inhibitor within 4 weeks prior to the first dose of sarilumab
- •-Treatment with any investigational biologic or non-biologic product within 8 weeks or 5 half-lives prior to baseline, whichever is longer.
- •-Exclusion criteria related to past or current infection other than tuberculosis.
- •-Any live, attenuated vaccine within 4 weeks prior to the baseline, such as varicella-zoster, oral polio, rubella vaccines;-Wheelchair-bound or bed ridden
- •- Diagnosis of JIA subtypes except polyarticular RF positive (RF+) or RF negative (RF ) JIA or extended oJIA
- •-Use of parenteral or intra-articular glucocorticoid injection within 4 weeks prior to Baseline
- •-Lipid-lowering drug stable for less than 6 weeks prior to screening.
- •-Exclusion related to tuberculosis (TB)
- •-Prior or current history of malignancy
- •-Prior or current history of other significant concomitant illness(es) that, according to the investigator*s judgment, would adversely affect the patient*s participation in the study.
- •-Patient with nonhealed/healing skin ulcers
- •-Surgery within 4 weeks prior to the screening visit or planned surgery during the course of the study.
- •- History of a systemic hypersensitivity reaction, other than localized injection site reaction, to any biologic drug and known hypersensitivity to any constituent of the product
- •-History of inflammatory bowel disease, severe diverticulitis, or previous gastrointestinal perforation whatever the cause
- •-Uncontrolled diabetes mellitus, defined as glycosylated hemoglobin (HbA1c) >=9% at the Screening visit
研究者
相似试验
已完成
2 期
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid TumorsNL-OMON48575CytomX Therapeutics, Inc.22
已完成
不适用
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination with M9241 (NHS-IL12) in Subjects with Locally Advanced, Unresectable, or Metastatic Solid TumorsCancerNL-OMON48631Merck KGaA7
已完成
3 期
A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19corona virusCOVID-19SARS-CoV-2100276651004743810024970NL-OMON51772Erasmus MC, Universitair Medisch Centrum Rotterdam100
已完成
3 期
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin*s Lymphoma (iNHL) - The COASTAL Studycancer from white blood cellsLymph node cancer. Recurringslow growing10025322NL-OMON51210MEI Pharma Inc.1
已完成
3 期
A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosisprimary amyloidosisprimary systemic amyloidosis (PSA)10035227NL-OMON50586Millenium Pharmaceuticals7